Sobi, a leading integrated global biopharmaceutical company dedicated to rare and difficult-to-treat diseases, announced today that Trista Morrison, an experienced corporate communications leader and former journalist, has joined the company as vice president of communications for North America.
Morrison will support Sobi’s growth in the region by building the communications function in North America and strengthening Sobi’s connection with patients, caregivers, healthcare professionals, advocacy groups and potential partners. She will also collaborate closely with the Sobi global communications team on integrated, worldwide communications initiatives.
Morrison’s more than 15 years in biopharmaceutical communications span corporate, reporter and agency roles. Most recently, Morrison served as director of corporate communications for Ironwood Pharmaceuticals, where she led internal, external and brand communications as the company transitioned from a research and development organization to a fully integrated commercial biotechnology company. Prior to her role at Ironwood, Morrison served as an editor and staff writer at BioWorld Today, covering breaking news and trends in the biopharmaceutical industry. Previously she served in various positions with biopharmaceutical-focused public relations agency Porter Novelli Life Sciences (formerly Atkins + Associates). Morrison was honored as one of PR News’ Top Women in PR in 2017, which recognizes communicators who have made bold advances in the profession.
“Sobi is a pioneer in rare and difficult-to-treat diseases, striving to create a world where patients with these conditions are diagnosed at birth and receive the care they need throughout their lives,” said Rami Levin, president of Sobi in North America. “This is an ambitious goal that requires communication and partnership between multiple stakeholders, and we look forward to working with Trista to advance this important work in North America.”
“The Sobi team is incredibly passionate about the work we do and dedicated to the patients and communities we serve. I am proud to be a part of this team and look forward to increasing our communication with key stakeholders as our business continues to grow,” said Morrison.
Source: Sobi™
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
